Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SNY 
Sanofi ADR (SNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SNY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $61.61
1 Year Target Price $61.61
| 5 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.91% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 115.18B USD | Price to earnings Ratio 15.62 | 1Y Target Price 61.61 |
Price to earnings Ratio 15.62 | 1Y Target Price 61.61 | ||
Volume (30-day avg) 11 | Beta 0.44 | 52 Weeks Range 43.86 - 57.57 | Updated Date 09/15/2025 |
52 Weeks Range 43.86 - 57.57 | Updated Date 09/15/2025 | ||
Dividends yield (FY) 8.23% | Basic EPS (TTM) 3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.95% | Operating Margin (TTM) 18% |
Management Effectiveness
Return on Assets (TTM) 4.61% | Return on Equity (TTM) 9% |
Valuation
Trailing PE 15.62 | Forward PE 9.38 | Enterprise Value 123554909680 | Price to Sales(TTM) 2.52 |
Enterprise Value 123554909680 | Price to Sales(TTM) 2.52 | ||
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA 8.35 | Shares Outstanding 2438960128 | Shares Floating 1096031708 |
Shares Outstanding 2438960128 | Shares Floating 1096031708 | ||
Percent Insiders - | Percent Institutions 10.28 |
Upturn AI SWOT
Sanofi ADR
Company Overview
History and Background
Sanofi ADR's history traces back to the 2004 merger of Sanofi-Synthu00e9labo and Aventis. Sanofi-Synthu00e9labo was created in 1999 by the merger of Sanofi and Synthu00e9labo. Aventis was created in 1999 by the merger of Rhu00f4ne-Poulenc and Hoechst Marion Roussel. They have since grown through acquisitions and internal development, becoming a leading global pharmaceutical company.
Core Business Areas
- Pharmaceuticals: Focuses on prescription drugs, including specialty care (immunology, oncology, rare diseases, neurology) and general medicines.
- Vaccines: Developed and manufactured by Sanofi Pasteur, this segment provides a range of vaccines for various diseases.
- Consumer Healthcare: Offers over-the-counter (OTC) medications and personal care products.
Leadership and Structure
The CEO of Sanofi is Paul Hudson. Sanofi operates with a global organizational structure, with key business units focused on Pharmaceuticals, Vaccines, and Consumer Healthcare. The board of directors oversees the company's strategy and performance.
Top Products and Market Share
Key Offerings
- Dupixent: A biologic medicine used to treat atopic dermatitis, asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyposis. Dupixent's global sales were $10.7 Billion in 2023. Sanofi and Regeneron collaborate on Dupixent. Competitors include AbbVie's Rinvoq and Pfizer's Cibinqo.
- Vaccines Portfolio: Sanofi Pasteur offers a broad range of vaccines for influenza, polio, meningitis, and other diseases. Sales are dependent on the vaccine type and geography. Competitors include GSK and Merck.
- Lantus: A long-acting insulin used to treat diabetes. While no longer under patent protection, it still generates revenue. Competitors include Novo Nordisk's Tresiba and Eli Lilly's Basaglar.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and patent expirations. Growth is driven by innovation, aging populations, and increasing healthcare access.
Positioning
Sanofi ADR is a major player in the pharmaceutical and vaccine markets, with a strong focus on specialty care and innovation. Its competitive advantages include a diverse product portfolio, global reach, and R&D capabilities.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be worth over $1.4 trillion. Sanofi ADR is positioned to address a substantial portion of this market through its diverse product offerings, especially in specialty care and vaccines.
Upturn SWOT Analysis
Strengths
- Strong global presence and distribution network
- Diverse product portfolio across pharmaceuticals, vaccines, and consumer healthcare
- Robust R&D capabilities and pipeline
- Established brands and market leadership in key therapeutic areas
Weaknesses
- Reliance on key products facing patent expirations
- Exposure to generic competition
- Complex regulatory environment
- High R&D costs
Opportunities
- Expansion in emerging markets
- Development of innovative therapies in high-growth areas such as oncology and immunology
- Strategic acquisitions and partnerships
- Increasing demand for vaccines
Threats
- Generic erosion of key products
- Pricing pressures from governments and payers
- Competition from other pharmaceutical companies
- Regulatory changes and uncertainties
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVO
Competitive Landscape
Sanofi competes with other major pharmaceutical companies in various therapeutic areas. Its strengths include a diverse product portfolio and global presence, but faces intense competition and pricing pressures.
Major Acquisitions
Provention Bio
- Year: 2023
- Acquisition Price (USD millions): 2900
- Strategic Rationale: Strengthen Sanofi's presence in immune-mediated diseases, specifically in type 1 diabetes prevention.
Tidal Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 470
- Strategic Rationale: Gain access to Tidal's mRNA-based platform for targeted immunotherapy.
Growth Trajectory and Initiatives
Historical Growth: Sanofi's growth has been driven by key products, acquisitions, and geographic expansion. It also had challenges from patent expiries
Future Projections: Analysts project moderate revenue growth. They depend on the successful launch of new products and the expansion of existing therapies. They anticipate Dupixent Sales to continue to drive growth.
Recent Initiatives: Sanofi focuses on strategic acquisitions and partnerships. Investment in R&D is also a key priority.
Summary
Sanofi is a major pharmaceutical company with a diversified portfolio and global reach. Growth is dependent on its pipeline and the performance of key products like Dupixent. The company faces challenges from patent expirations and competitive pressures, but is actively investing in innovation and strategic acquisitions. With strong cash flows Sanofi is able to make strategic changes as needed. The company needs to improve its year over year performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sanofi's annual reports
- Analyst reports
- Company press releases
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and may vary depending on the source. Financial data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanofi ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2002-07-01 | CEO & Director Mr. Paul Hudson | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 82878 | Website https://www.sanofi.com |
Full time employees 82878 | Website https://www.sanofi.com | ||
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.